- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Milken Institute's Sarah Wells Kocsis Highlights Key Findings of Her Research on CKD
Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).
Sarah Wells Kocsis, MBA, director of the Center for Public Health at the Milken Institute, talks about the key findings of her recently authored report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.”
Transcript
What are the biggest takeaways of your research?
Chronic kidney disease [CKD] is a huge public health problem. It's intricately tied to health equity and social determinants of health. So tackling CKD is going to require a major shift in our mindset and the approach. Roughly 1 in 7 adults have chronic kidney disease, and 9 out of 10 of them don't even know that they have it, so we really need to listen to what the research is telling us. And what it's telling us is that we really need to focus right now on root causes, and these causes are structural, social, and health related. That's going to require practical, scalable, equitable solutions aimed at both detecting and managing the condition upstream at earlier stages and focusing on reducing the burden of this debilitating disease.
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
Infant Mortality Increases Across US Following Dobbs Decision
October 25th 2024The Dobbs decision was associated with a 7% absolute increase in overall infant mortality—equivalent to 247 excess deaths—and a 10% increase among infants with congenital anomalies, corresponding to 204 additional deaths.
Read More
